About

Oren Cahlon, MD, is a professor in the Department of Radiation Oncology at NYU Grossman School of Medicine and holds the position of Executive Vice President, Vice Dean for Clinical Affairs and Strategy, and Chief Clinical Officer at NYU Langone Health. He specializes in radiation oncology, with a focus on treating breast cancer, including advanced or metastatic cases, at NYU Langone’s Perlmutter Cancer Center. Dr. Cahlon is passionate about radiation therapy as it allows him to combine his appreciation for advanced technology, math, and physics with compassionate patient care. His approach involves recommending personalized radiation treatments based on each patient's medical history, age, and cancer type, aiming to balance disease control with minimizing side effects and long-term treatment impacts. He has extensive experience seeing thousands of breast cancer patients, which informs his dedication to building relationships and providing hope and optimism to his patients. His research concentrates on identifying the most effective radiation therapy techniques for breast cancer, including proton therapy, partial breast radiation, and short- versus long-course radiation. He studies the long-term effects of radiation, such as the risk of heart disease, and works on modern radiation techniques to protect the heart from radiation damage. Dr. Cahlon is the co-principal investigator of a national phase 3 clinical trial testing proton therapy for breast cancer. He is a member of the American Board of Radiology and the American Society for Radiation Oncology, and has held leadership roles in the Proton Collaborative Group. His goal is to ensure that NYU Langone meets patients' clinical needs efficiently, affordably, and conveniently across its various locations.

Research topics

• Medicine
• Internal medicine
• Nuclear medicine
• Oncology
• Surgery

Selected publications

• Impact of a Dedicated Inpatient Radiation Oncology Consult Service on Goal-Concordant Care

  Advances in Radiation Oncology · 2025-10-25

  articleOpen access

  <h2>Abstract</h2><h3>Purpose</h3> Radiotherapy has an increasing role in the management of metastatic cancers. Integrating radiation with surgical and systemic approaches is complex, and inappropriate management can lead to prolonged hospitalizations inconsistent with palliative goals. An Inpatient Radiation Oncology Consult (IROC) service was created in January 2020 to provide rapid access to specialized care for hospitalized patients. Here we report outcomes of the IROC service, focusing on quality-of-care metrics including hospital length-of-stay (LOS), use of hypofractionated approaches, and treatments for patients discharged to hospice. <h3>Methods and Materials</h3> We conducted a pre-post observational study to compare inpatient consults placed before (<i>N</i> = 1,507) and after (<i>N</i> = 1,509) IROC, from 2019-2021. Continuous variables were analyzed using the Mann-Whitney test and categorical variables using the Fisher's exact test. <h3>Results</h3> We found that IROC was associated with reductions in hospital length of stay (LOS, mean difference 1.0 days, <i>P</i> = 0.045). Under IROC, inpatient treatment courses were shorter (5.8 <i>v</i> 5.0 days, <i>P</i> = 0.007), in part driven by increased adoption of palliative hypofractionated radiotherapy approaches (74% <i>v</i> 82%, <i>P</i> = 0.001). The reduction in LOS was greatest for patients discharged to hospice (5.1 <i>v</i> 3.7 days, <i>P</i> = 0.036). <h3>Conclusions</h3> The IROC service was associated with reduced hospital LOS, increased use of hypofractionated approaches and decreased treatments for patients discharged to hospice. Our findings demonstrate the value of a dedicated program addressing radiation delivery to hospitalized patients to improve goal-concordant treatments. The financial impact of reducing low value care is an important subject for future investigations.

  PublisherOA PDFDOI

• Objective Analysis of Fibrosis via Shear Wave Elastography after Post Mastectomy Radiation

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

  article
  PublisherDOI

• Accelerated Partial Breast Irradiation in the Supine vs. Prone Position: A Comparison of Dosimetry and Acute Toxicity

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

  article
  PublisherDOI

• Long Term Outcomes in Women ≥ 70 years old with Early-Stage Breast Cancer as Stratified by EUROPA Trial Eligibility

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

  article
  PublisherDOI

• Five vs. Three Fractions of Prone Accelerated Partial Breast Irradiation: Results of a Randomized Controlled Phase 3 Non-Inferiority Trial

  International Journal of Radiation Oncology*Biology*Physics · 2024-09-27

  article
  PublisherDOI

• Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial

  International Journal of Radiation Oncology*Biology*Physics · 2024-05-13 · 3 citations

  articleOpen access
  PublisherOA PDFDOI

• A Phase I/II Trial of Spectrophotometric Skin Changes during and after Radiotherapy and Correlation with Radiation-Induced Skin Toxicity in Breast Cancer Patients with Skin of Color

  International Journal of Radiation Oncology*Biology*Physics · 2024-09-27 · 1 citations

  article
  PublisherDOI

• Echocardiographic Functional Outcomes Following Regional Nodal Irradiation for Breast Cancer Using Volumetric Modulated Arc Therapy

  Advances in Radiation Oncology · 2024-07-25 · 1 citations

  articleOpen access

  Purpose: Regional nodal irradiation (RNI) for breast cancer yields improvements in disease outcomes, yet comprehensive target coverage often increases cardiac radiation therapy (RT) dose. Volumetric modulated arc therapy (VMAT) may mitigate high-dose cardiac exposure, although it often increases the volume of low-dose exposure. The cardiac implications of this dosimetric configuration (in contrast to historic 3D conformal techniques) remain uncertain. Methods and Materials: Eligible patients receiving adjuvant RNI using VMAT for locoregional breast cancer were prospectively enrolled in an IRB-approved study. Echocardiograms were performed prior to RT, at the conclusion of RT, and 6 months following RT. Echocardiographic parameters were measured by a single reader and measures were compared pre- and post-RT via the signed-rank test. Changes in echocardiographic parameters over time were compared to mean and max heart doses via the Spearman correlation test. Results: > .1 for all). Conclusions: VMAT for left-sided RNI yielded no significant early decrement in echocardiographic parameters of cardiac function, including LVEF and GLS, within this limited cohort. No patient exhibited significant LVEF changes, and none exhibited sustained decrements in GLS. VMAT may be a reasonable approach to cardiac avoidance in patients requiring RNI, including those receiving anthracyclines and HER2-directed therapy. Larger cohorts with longer follow-ups will be needed to validate these findings.

  PublisherDOI

• Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation

  Breast Cancer Research and Treatment · 2024-01-06 · 2 citations

  article
  PublisherDOI

• A Radiation Therapy Contouring Atlas for Delineation of the Level I and II Axillae in the Prone Position: A Single-Institution Experience

  Practical Radiation Oncology · 2024-05-08 · 2 citations

  article
  PublisherDOI

Frequent coauthors

• Lior Z. Braunstein

  Memorial Sloan Kettering Cancer Center

  61 shared

• Beryl McCormick

  Memorial Sloan Kettering Cancer Center

  58 shared

• Erin F. Gillespie

  University of Washington

  56 shared

• Simon N. Powell

  Memorial Sloan Kettering Cancer Center

  56 shared

• Atif J. Khan

  52 shared

• John Cuaron

  Memorial Sloan Kettering Cancer Center

  30 shared

• Eugen B. Hug

  27 shared

• Brian H. Chon

  ProCure (United States)

  24 shared

Awards & honors

• American Board of Radiology - Radiation Oncology (2010)